{"id":"NCT05248386","sponsor":"Gr√ºnenthal GmbH","briefTitle":"Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Intra-articular Injections of RTX-GRT7039 in Adult Subjects With Pain Associated With Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-26","primaryCompletion":"2024-11-18","completion":"2024-11-18","firstPosted":"2022-02-21","resultsPosted":"2025-08-12","lastUpdate":"2025-08-12"},"enrollment":469,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis"],"interventions":[{"type":"DRUG","name":"RTX-GRT7039","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RTX-GRT7039","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated injections of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.","primaryOutcome":{"measure":"Least Squares Mean (Standard Error) [LS-mean (SE)] Change From Baseline in WOMAC Pain Subscale Score at Week 12","timeFrame":"Baseline up to Week 12","effectByArm":[{"arm":"RTX-GRT7039","deltaMin":-2.959,"sd":0.15},{"arm":"Placebo","deltaMin":-2.847,"sd":0.15}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":103,"countries":["Canada","Czechia","France","Germany","Italy","Japan","Mexico","Netherlands","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":234},"commonTop":["Procedural pain","Arthralgia","Nasopharyngitis"]}}